The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...

Microdosing glp-1 is gaining traction, but is it safe? Experts warn about compounded semaglutide, reduced efficacy, and ...

Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

The bold move has been accompanied by a full-page ad in the Wall Street Journal explaining its reasoning, and claiming that the prices of GLP-1 drugs for weight loss are five times too high and ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

The miracle weight loss drug, sold as injection 'pens' for £170, is appearing on drug menus alongside ADHD medication Ritalin ...

Clinical neuroscientist Joe Schacht offered an overview of the research on weight-loss drugs for alcoholism, other potential ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Generic drugmaker Granules India is foraying into the peptide segment and contract development and manufacturing organisation (CDMO) business with a ₹192.5 crore (CHF 20 million) acquisition of Swiss ...

The clinical Phase I study conducted in the NEX-22 project with good results and focus on the evaluation with Novo Nordisk has provided a good starting point for 2025. Significant events during the fo ...